diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM13295diaendo-13295Research ArticleОбзорыReviewКардиодиабетология: эволюция или революция?Cardiodiabetology: Evolution or Revolution?https://orcid.org/0000-0002-5178-6029БондаренкоИ. З.BondarenkoI. Z.

Бондаренко Ирина Зиятовна, д.м.н. 

117036, Москва, ул. Дм. Ульянова, д. 11

Irina Z. Bondarenko, MD, PhD

11 Dm. Ulyanova street, 117036 Moscow

bondarenko.irina@endocrincentr.ruhttps://orcid.org/0000-0001-5573-0754КалашниковВ. Ю.KalashnikovV. Y.

Калашников Виктор Юрьевич, д.м.н., профессор, член-корреспондент РАН

117036, Москва, ул. Дм. Ульянова, д. 11

Victor Y. Kalashnikov, MD, PhD, Professor

11 Dm. Ulyanova street, 117036 Moscow

victor9368@gmail.comГНЦ РФ ФГБУ «Национальный медицинский исследовательский центр эндокринологии»РоссияEndocrinology Research CentreRussian Federation2025010220252813845Copyright © Бондаренко И.З., Калашников В.Ю., 20252025Бондаренко И.З., Калашников В.Ю.Bondarenko I.Z., Kalashnikov V.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/13295

 Статья посвящена современным проблемам эндокринной кардиологии. Основное содержание работы составляет анализ истории лекарственных препаратов, применяемых в диабетологии, начиная от первых инсулинов животного происхождения до современных ингибиторов натрий-глюкозного котранспортера ٢ типа (НГЛТ-2) и агонистов рецепторов глюкагоноподобного пептида-1 (арГПП-1), обладающих выраженной кардиопротективной активностью. Проанализированы исследования, в которых доказана эффективность их влияния на сердечно-сосудистую систему у пациентов с сахарным диабетом ٢ типа (СД٢). Особое внимание уделяется многоцентровым клиническим исследованиям, которые изучали влияние гипогликемии на сердечно-сосудистые исходы у пациентов с СД2. Также в статье обобщается научный и практический опыт применения ингибиторов НГЛТ-2 у пациентов с различными нарушениями сердечного ритма, в том числе представляющими угрозу жизни для пациентов с СД٢.

This article addresses contemporary issues in endocrine cardiology. The main content of the work is an analysis of the history of medications used in diabetology, ranging from the first animal-derived insulins to modern sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide-1 receptor agonists (GLP-1 RA), which possess pronounced cardioprotective activity. Studies demonstrating their effectiveness in influencing the cardiovascular system in patients with type 2 diabetes mellitus (T2DM) are analyzed. Particular attention is paid to multicenter clinical trials that studied the effect of hypoglycemia on cardiovascular outcomes in patients with T2DM. The article also summarizes the scientific and practical experience of using SGLT2 inhibitors in patients with various cardiac arrhythmias, including those that are life-threatening for patients with T2DM.

сахарный диабет 2 типасердечно-сосудистые заболеванияингибиторы НГЛТ-2агонисты рецепторов ГПП-1гипогликемииtype 2 diabetes mellituscardiovascular diseasesSGLT2 inhibitorsGLP-1 receptor agonistshypoglycemiaReferencesMcKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441-1446. doi: https://doi.org/10.1056/NEJM197112232852601McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441-1446. doi: https://doi.org/10.1056/NEJM197112232852601Preiss D, Zetterstrand S, McMurray JJ, et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care. 2009;32(5):915-920. doi: https://doi.org/10.2337/dc08-1709Preiss D, Zetterstrand S, McMurray JJ, et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care. 2009;32(5):915-920. doi: https://doi.org/10.2337/dc08-1709Kristensen SL, Preiss D, Jhund PS, et al. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016;9(1):e002560. doi: https://doi.org/10.1161/CIRCHEARTFAILURE.115.002560Kristensen SL, Preiss D, Jhund PS, et al. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016;9(1):e002560. doi: https://doi.org/10.1161/CIRCHEARTFAILURE.115.002560Kristensen SL, Jhund PS, Lee MMY, et al. Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. Cardiovasc Drugs Ther. 2017;31(5-6):545-549. doi: https://doi.org/10.1007/s10557-017-6754-xKristensen SL, Jhund PS, Lee MMY, et al. Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. Cardiovasc Drugs Ther. 2017;31(5-6):545-549. doi: https://doi.org/10.1007/s10557-017-6754-xMarre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) [published correction appears in BMJ. 2004 Mar 20;328(7441):686]. BMJ. 2004;328(7438):495. doi: https://doi.org/10.1136/bmj.37970.629537.0DMarre M, Lievre M, Chatellier G, et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) [published correction appears in BMJ. 2004 Mar 20;328(7441):686]. BMJ. 2004;328(7438):495. doi: https://doi.org/10.1136/bmj.37970.629537.0DNissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007 Jul 5;357(1):100.]. N Engl J Med. 2007;356(24):2457-2471. doi: https://doi.org/10.1056/NEJMoa072761Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007 Jul 5;357(1):100.]. N Engl J Med. 2007;356(24):2457-2471. doi: https://doi.org/10.1056/NEJMoa072761Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet 1998 Nov 7;352(9139):1558]. Lancet. 1998;352(9131):854-865Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet 1998 Nov 7;352(9139):1558]. Lancet. 1998;352(9131):854-865Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289. doi: https://doi.org/10.1016/S0140-6736(05)67528-9Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289. doi: https://doi.org/10.1016/S0140-6736(05)67528-9Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016;374(14):1321-1331. doi: https://doi.org/10.1056/NEJMoa1506930Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016;374(14):1321-1331. doi: https://doi.org/10.1056/NEJMoa1506930Schmidt MR, Smerup M, Konstantinov IE, et al. Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning. Am J Physiol Heart Circ Physiol. 2007;292(4):H1883-H1890. doi: https://doi.org/10.1152/ajpheart.00617.2006Schmidt MR, Smerup M, Konstantinov IE, et al. Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning. Am J Physiol Heart Circ Physiol. 2007;292(4):H1883-H1890. doi: https://doi.org/10.1152/ajpheart.00617.2006Malmberg K, Rydén L, Hamsten A, Herlitz J, Waldenström A, Wedel H. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study [published correction appears in Cariovasc Res 1997 Dec;36(3):460]. Cardiovasc Res. 1997;34(1):248-253. doi: https://doi.org/10.1016/s0008-6363(96)00263-5Malmberg K, Rydén L, Hamsten A, Herlitz J, Waldenström A, Wedel H. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study [published correction appears in Cariovasc Res 1997 Dec;36(3):460]. Cardiovasc Res. 1997;34(1):248-253. doi: https://doi.org/10.1016/s0008-6363(96)00263-5Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. doi: https://doi.org/10.1002/ejhf.592Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. doi: https://doi.org/10.1002/ejhf.592Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326. doi: https://doi.org/10.1056/NEJMoa1307684Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326. doi: https://doi.org/10.1056/NEJMoa1307684Standards of medical care in diabetes — 2015: summary of revisions. Diabetes Care. 2015;38Suppl:S4. doi: https://doi.org/10.2337/dc15-S003Standards of medical care in diabetes — 2015: summary of revisions. Diabetes Care. 2015;38Suppl:S4. doi: https://doi.org/10.2337/dc15-S003Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247-2257. doi: https://doi.org/10.1056/NEJMoa1509225Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247-2257. doi: https://doi.org/10.1056/NEJMoa1509225Buse JB; the LEADER Steering Committee. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(18):1798-1799. doi: https://doi.org/10.1056/NEJMc1611289Buse JB; the LEADER Steering Committee. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(18):1798-1799. doi: https://doi.org/10.1056/NEJMc1611289Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: https://doi.org/10.1056/NEJMoa1607141Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: https://doi.org/10.1056/NEJMoa1607141Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi: https://doi.org/10.1056/NEJMoa1504720Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi: https://doi.org/10.1056/NEJMoa1504720Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017;136(17):1643-1658. doi: https://doi.org/10.1161/CIRCULATIONAHA.117.030012Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017;136(17):1643-1658. doi: https://doi.org/10.1161/CIRCULATIONAHA.117.030012McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021 Dec 21;42(48):4901. doi: 10.1093/eurheartj/ehab670]. Eur Heart J. 2021;42(36):3599-3726. doi: https://doi.org/10.1093/eurheartj/ehab368McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart J. 2021 Dec 21;42(48):4901. doi: 10.1093/eurheartj/ehab670]. Eur Heart J. 2021;42(36):3599-3726. doi: https://doi.org/10.1093/eurheartj/ehab368Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997-4126. doi: https://doi.org/10.1093/eurheartj/ehac262Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997-4126. doi: https://doi.org/10.1093/eurheartj/ehac262Packer M. What causes sudden death in patients with chronic heart failure and a reduced ejection fraction? Eur Heart J. 2020;41(18):1757-1763. doi: https://doi.org/10.1093/eurheartj/ehz553Packer M. What causes sudden death in patients with chronic heart failure and a reduced ejection fraction? Eur Heart J. 2020;41(18):1757-1763. doi: https://doi.org/10.1093/eurheartj/ehz553Ferrannini E, Baldi S, Frascerra S, et al. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016;65(5):1190-1195. doi: https://doi.org/10.2337/db15-1356Ferrannini E, Baldi S, Frascerra S, et al. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016;65(5):1190-1195. doi: https://doi.org/10.2337/db15-1356Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients [published correction appears in J Clin Invest. 2014 Apr 1;124(4):1868]. J Clin Invest. 2014;124(2):499-508. doi: https://doi.org/10.1172/JCI72227Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients [published correction appears in J Clin Invest. 2014 Apr 1;124(4):1868]. J Clin Invest. 2014;124(2):499-508. doi: https://doi.org/10.1172/JCI72227Liao J, Ebrahimi R, Ling Z, et al. Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i-Arrhythmias and Sudden Cardiac Death). Cardiovasc Diabetol. 2024;23(1):78. doi: https://doi.org/10.1186/s12933-024-02137-xLiao J, Ebrahimi R, Ling Z, et al. Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i-Arrhythmias and Sudden Cardiac Death). Cardiovasc Diabetol. 2024;23(1):78. doi: https://doi.org/10.1186/s12933-024-02137-xHabibi J, Aroor AR, Sowers JR, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9. doi: https://doi.org/10.1186/s12933-016-0489-zHabibi J, Aroor AR, Sowers JR, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9. doi: https://doi.org/10.1186/s12933-016-0489-zSato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17(1):6. doi: https://doi.org/10.1186/s12933-017-0658-8Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17(1):6. doi: https://doi.org/10.1186/s12933-017-0658-8Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021;42(36):3727-3738. doi: https://doi.org/10.1093/eurheartj/ehab560Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021;42(36):3727-3738. doi: https://doi.org/10.1093/eurheartj/ehab560Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск // Сахарный диабет. — 2023. — Т.26. — №2S. — С.1-157. doi: https://doi.org/10.14341/DM13042Dedov II, Shestakova MV, Mayorov AY, et al. Standards of Specialized Diabetes Care / Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11th Edition. Diabetes mellitus. 2023;26(2S):1-157. (In Russ.) doi: https://doi.org/10.14341/DM13042American Diabetes Association Professional Practice Committee; Introduction and Methodology: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(S1):S1–S5. doi: https://doi.org/10.2337/dc25-SINTAmerican Diabetes Association Professional Practice Committee; Introduction and Methodology: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(S1):S1–S5. doi: https://doi.org/10.2337/dc25-SINT

The authors declare that there are no conflicts of interest present.